How to Get Repatha (Evolocumab) in Wisconsin

What Is Repatha and Why Wisconsin Patients Ask About It

Repatha is a PCSK9-inhibitor monoclonal antibody that lowers LDL-cholesterol by an average of 59% when added to maximally tolerated statin therapy. Wisconsin has roughly 1.2 million adults living with cardiovascular disease according to CDC state data, and a meaningful share of those patients never reach their LDL-C goal on statins alone. That gap is exactly the therapeutic space evolocumab occupies.

The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond diet and statin therapy. The FDA prescribing information for Repatha lists the approved dosage as 140 mg subcutaneously every two weeks or 420 mg subcutaneously once monthly, both delivered via a prefilled autoinjector or prefilled syringe.

The cardiovascular outcomes data behind the drug come primarily from FOURIER, a phase 3 randomized controlled trial published in the New England Journal of Medicine in 2017. FOURIER enrolled 27,564 patients with established ASCVD on optimized statin therapy and found that evolocumab reduced the primary composite endpoint (CV death, MI, stroke, coronary revascularization, or unstable angina hospitalization) by 15% compared with placebo over a median follow-up of 2.2 years (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001).

Who Can Prescribe Repatha in Wisconsin

Any Wisconsin-licensed prescriber with Schedule II-V DEA registration authority can write a Repatha prescription, though Repatha itself is not a controlled substance. That group includes MDs, DOs, nurse practitioners (NPs) with full prescriptive authority, and physician assistants (PAs) collaborating with a supervising physician.

Wisconsin NPs hold full practice authority under Wisconsin Act 90 (2017), meaning an NP does not need a physician co-signature to prescribe Repatha. PAs in Wisconsin operate under a written collaboration agreement, but that agreement does not bar them from prescribing non-controlled medications including biologics.

Cardiologists and lipidologists are the most common prescribers. Primary care physicians write a significant volume as well, particularly in rural Wisconsin counties where specialty access is limited. The telehealth pathway described below broadens access to patients who live more than 60 miles from the nearest lipid specialist, which covers a large portion of the state's northern and western counties.

How to Get Repatha Through a Wisconsin Telehealth Provider

Wisconsin permits telehealth prescribing of non-controlled medications, and evolocumab qualifies. A telehealth visit with a licensed Wisconsin provider can result in a valid Repatha prescription sent electronically to a specialty pharmacy.

The standard telehealth pathway looks like this. A patient schedules a video or phone consultation, uploads recent lab work (a fasting lipid panel drawn within the past 6 to 12 months is acceptable to most prescribers), and provides documentation of prior statin trials. The clinician reviews the data, confirms the ASCVD or FH diagnosis, and sends the e-prescription to a specialty pharmacy along with the prior authorization paperwork.

The prescriber must hold an active Wisconsin medical license. Under the Wisconsin Telemedicine Act and subsequent guidance from the Wisconsin Medical Examining Board, an initial prescribing relationship may be established via synchronous audio-video without a prior in-person encounter for most non-controlled drugs. Repatha fits that category cleanly.

HealthRX connects Wisconsin patients with board-certified clinicians licensed in Wisconsin who can evaluate candidacy for PCSK9 inhibitor therapy and, where appropriate, initiate the prescription and PA process in a single appointment.

Labs and Clinical Documentation Needed Before Starting

Getting labs right before the visit saves time. Most prescribers and nearly every insurance prior authorization form require the same core set.

Fasting lipid panel. The LDL-C value is the single most important number. Most prior authorization criteria for commercial plans in Wisconsin require LDL-C of 70 mg/dL or above (for established ASCVD patients) or 100 mg/dL or above (for FH patients without ASCVD) despite maximally tolerated statin therapy. Draw the panel after a 9-to-12-hour fast. Results from a certified lab in the past 6 months are typically accepted.

Statin trial documentation. Wisconsin Medicaid (ForwardHealth) and most commercial plans require evidence of a trial of at least two statins at maximally tolerated doses, or documentation of statin intolerance with the specific adverse effect noted in the chart. A printed or electronically exported medication history from a pharmacy or EHR is the cleanest form of evidence.

Basic metabolic panel or comprehensive metabolic panel. Baseline creatinine and liver function tests are standard before starting a new lipid-lowering agent, even though evolocumab has not shown hepatotoxicity in trials.

Genetic testing (if FH is suspected). A Dutch Lipid Clinic Network score of 6 or above suggests probable or definite FH. Genetic confirmation of a pathogenic LDLR, APOB, or PCSK9 variant strengthens the PA application and may allow bypass of the statin failure requirement in some plans. The American College of Cardiology/AHA 2018 Cholesterol Guideline states that genetic testing is "reasonable" when the diagnosis of FH would meaningfully change management.

The HealthRX clinical team uses a four-gate screening checklist for Wisconsin patients seeking PCSK9 inhibitor therapy. Gate 1 confirms a qualifying diagnosis (HeFH, HoFH, or established ASCVD). Gate 2 verifies LDL-C above threshold on a documented maximally tolerated statin dose or confirms statin intolerance. Gate 3 reviews contraindications and pregnancy status. Gate 4 confirms the patient's Wisconsin insurance plan and opens the PA file before the prescription is sent.

Prior Authorization in Wisconsin: What the Forms Actually Ask

Prior authorization (PA) is required by virtually every Wisconsin payer for Repatha, and the PA denial rate is lower when the submission is complete on the first try.

Wisconsin ForwardHealth (Medicaid) covers evolocumab for HeFH and established ASCVD with PA. The PA criteria published by ForwardHealth require: (1) a diagnosis of HeFH confirmed by genetic testing or clinical criteria, or established ASCVD defined as prior MI, stroke, or symptomatic peripheral arterial disease; (2) LDL-C of 100 mg/dL or above on maximally tolerated statin therapy, or documented statin intolerance; and (3) a statement that the prescriber has reviewed current lipid guidelines.

For commercial plans operating in Wisconsin (including Anthem/BCBS WI, Quartz, Molina Wisconsin, and Common Ground Healthcare), the criteria are broadly similar. The 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies explicitly supports PCSK9 inhibitor use when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients despite maximally tolerated statin plus ezetimibe therapy. Including a reference to that document in a PA appeal tends to strengthen the clinical argument.

Appeals succeed more often when the clinician's letter includes specific LDL-C values with dates, the name and dose of each statin tried, the duration of each trial, and the outcome (inadequate response or intolerance). Vague language like "patient tried statins" is the single most common reason a first-round PA is denied.

Wisconsin Pharmacy Options: Specialty, Retail, and 503A Compounding

Repatha is a specialty biologic and must be dispensed through a specialty pharmacy, even though a retail pharmacist can technically receive the e-prescription. In practice, most chain retail pharmacies in Wisconsin will route the prescription to their specialty pharmacy arm.

Specialty pharmacy. Amgen's Repatha SupportPlus program connects prescribers and patients directly to specialty pharmacies that handle the PA, coordinate cold-chain shipping, and offer a $0 co-pay card for commercially insured patients who qualify. Delivery to a Wisconsin address typically takes 2 to 7 business days after PA approval.

Retail pharmacy. CVS, Walgreens, and Hometown Pharmacies (a Wisconsin-based independent pharmacy cooperative) can dispense Repatha, but they often lack the specialty workflow for a biologic. Expect delays unless the prescriber or patient explicitly requests the specialty pharmacy channel.

503A compounding pharmacies. Wisconsin-licensed 503A pharmacies are permitted to compound medications for individual patients. Compounded evolocumab is not available as a standard offering because the proprietary monoclonal antibody sequence is not in the public domain, and no 503A pharmacy can legally replicate a biologic without a valid compounding pathway. What 503A pharmacies in Wisconsin can do is prepare supportive formulations (for example, preservative-free normal saline for injection site care), but they cannot substitute for branded Repatha. Any advertisement claiming a 503A can provide "generic evolocumab" should be treated with significant skepticism.

Cold-chain handling. Repatha must be stored between 36°F and 46°F (2°C to 8°C). Wisconsin winters create a shipping variable: the autoinjector should not freeze. Most specialty pharmacies use insulated packaging rated for 48-hour cold-chain integrity, but patients in rural Wisconsin may want to request delivery to a pharmacy rather than a residential mailbox in January.

Wisconsin Medicaid (ForwardHealth) Coverage Details

ForwardHealth covers both the 140 mg/mL single-dose prefilled syringe and the SureClick autoinjector under the preferred drug list (PDL) with PA. The monthly 420 mg dose kit is also covered.

Step therapy is required: the enrollee must have tried at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) before ForwardHealth will approve a PCSK9 inhibitor, unless the enrollee has documented rhabdomyolysis or a clinical contraindication to statins. Ezetimibe is not currently a mandatory step for ForwardHealth PA, though some commercial plans do require it.

The PA approval period for ForwardHealth is typically 12 months, after which a renewal PA must document ongoing LDL-C response (usually a repeat lipid panel showing at least a 50% LDL-C reduction from baseline, or LDL-C below 70 mg/dL).

Patients enrolled in a Wisconsin BadgerCare Plus plan follow the same ForwardHealth PDL criteria. The prescriber's NPI and taxonomy code must match the submitting provider record in the ForwardHealth portal, or the PA will reject on a technical rather than clinical basis.

How Long Does the Process Take in Wisconsin?

The timeline from first clinical contact to first injection has several moving parts.

A telehealth visit to confirm the diagnosis and initiate the PA can happen within 24 to 72 hours of scheduling with most Wisconsin-accessible telehealth platforms. Lab turnaround from a Wisconsin LabCorp or Quest draw site is 1 to 2 business days for a standard lipid panel.

Once the PA is submitted, ForwardHealth typically returns a decision within 3 to 5 business days for a standard review, or within 72 hours for an expedited review requested by the prescriber due to clinical urgency. Commercial plan decisions range from 3 days (some BCBS Wisconsin plans) to 15 calendar days (the maximum allowed under Wisconsin law for standard PA decisions per Wis. Stat. §632.835).

After PA approval, specialty pharmacy processing and cold-chain shipping add 2 to 7 business days. Total elapsed time from first telehealth visit to first injection is typically 10 to 21 calendar days for most Wisconsin patients with organized documentation.

Transferring an Existing Repatha Prescription to Wisconsin

Patients relocating to Wisconsin who already have an active Repatha prescription face a straightforward transfer process, with one potential complication: if the originating prescription was written by an out-of-state prescriber who is not licensed in Wisconsin, the prescription cannot simply be transferred. A Wisconsin-licensed prescriber must issue a new prescription.

The specialty pharmacy can typically support the clinical handoff if the patient provides records from the original prescriber. A telehealth appointment with a Wisconsin-licensed clinician to review the chart and issue a new prescription is the fastest path. The existing PA history from the prior state may accelerate the Wisconsin PA approval if it shows a documented LDL-C response to evolocumab, since this establishes clinical necessity and prior authorization precedent for the new payer.

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease notes that continuation of lipid-lowering therapy in patients with established ASCVD should not be interrupted without a clear clinical reason, reinforcing the importance of minimizing any gap in treatment during a state-to-state transition.

Dosing and Self-Injection Practical Points for Wisconsin Patients

The two approved dosing schedules give patients flexibility. The 140 mg every-two-weeks regimen uses a single autoinjector shot. The 420 mg once-monthly regimen uses three consecutive 140 mg injections given within 30 minutes, or a single 420 mg/3.5 mL prefilled syringe (the SureClick 420 mg device).

Patients self-injecting for the first time should rotate injection sites among the abdomen, thigh, or upper arm. The autoinjector should be removed from the refrigerator 30 minutes before injection to reduce injection-site discomfort. Wisconsin winters are relevant here: patients who leave the device in a cold car before injection may experience increased stinging.

The FOURIER trial investigators reported that injection-site reactions occurred in 2.1% of evolocumab-treated patients versus 1.6% of placebo patients, a difference that was statistically significant but clinically minor. Nasopharyngitis (6.0% vs. 5.5%) and back pain (3.2% vs. 2.9%) were the only other adverse events occurring at rates meaningfully higher than placebo.

Patients with latex allergy should use the prefilled syringe rather than the SureClick autoinjector; the needle cap of the autoinjector contains a latex derivative.

LDL-C response should be checked 4 to 8 weeks after initiation. A 50% or greater reduction from baseline is expected. If the response is below 40%, adherence and injection technique should be reviewed before concluding the drug is ineffective.

Cost and Patient Assistance Programs Accessible from Wisconsin

The list price for Repatha is approximately $700 per month for the every-two-weeks regimen. Most commercially insured Wisconsin patients pay far less due to Amgen's co-pay assistance program, which caps out-of-pocket costs at $0 per month for eligible patients (those with commercial insurance, not Medicaid or Medicare).

Medicare Part D covers Repatha. Wisconsin Medicare beneficiaries are subject to their plan's specialty tier cost-sharing, which may reach several hundred dollars per month before the catastrophic coverage phase. The Amgen SAFETY NET Foundation provides free Repatha to qualifying patients with incomes at or below 600% of the federal poverty level who have no insurance or whose insurance does not cover the drug.

Patient advocacy organizations including the FH Foundation offer Wisconsin-specific navigation support for patients with familial hypercholesterolemia who are facing coverage denials.